(FISH) with probes for BCR (on chromosome 22) and ABL (on chromosome 9). The patient's result of 77.6% nuclei with the BCR-ABL fusion gene is consistent with Ph chromosome. The Ph chromosome is a rare phenomenon in the acute leukemias. Approximately 2% to 5% of childhood ALL, 25% of adult ALL, and some cases of AML have the Ph chromosome. This finding is much more common in CML; approximately 90% to 95% of CML cases are Ph positive. 1, 5 4. The acute leukemias, ALL and AML, must be differentiated in order for proper diagnosis and treatment of the patient. Morphology is the first step in identification. In ALL, the small lymphoblasts have fine chromatin with scanty cytoplasm and small nucleoli. In AML, the large myeloblasts contain fine chromatin with abundant basophilic cytoplasm and prominent nucleoli. Auer rods may also be present on examination of the bone marrow. The second step to identification is cytochemistry analysis ( Table 2 ). Myeloperoxidase (MPO) and non-specific esterase (NSE) are the key stains used to identify AML, while ALL uses terminal deoxynucleotidyl transferase (TdT) and periodic acid schiff (PAS) stains for identification. Immunologic analysis with CD markers in flow cytometry can identify antigens on a cell surface and can differentiate the lineages based on their specific surface markers. Characteristically, AML blasts express CD13, CD15, and CD33, while ALL blasts express CD19, CD20, and CD22 or CD2, CD3, CD5, and CD7. 1 Further classification into a B-or T-cell lineage of ALL requires immunophenotyping with CD markers (Table 3) . Immunophenotyping includes CD markers and analysis of the TCR or BCR gene rearrangement. Common CD antigens of the T-cell lineage include CD2, CD3, CD5, and CD7. The B-cell lineage markers include CD10, CD19, CD20, and CD22.
BCR-ABL-expressing
ALL has poor cure rates with conventional chemotherapy. 4, 6, 7 Allogeneic hematopoietic stem cell transplantation has shown improvement in outcome for 
